Labels
Breast Cancers
(143)
Genitourinary Cancers
(71)
Lung Cancers
(70)
Gastrointestinal Cancers
(66)
Gynecological Cancers
(55)
Head and Neck Cancers
(49)
Cutaneous Cancers
(21)
Central Nervous System Cancers
(11)
Friday 9 August 2013
VOTRIENT (pazopanib hydrochloride) - Important change to frequency of liver test monitoring
GlaxoSmithKline Inc., in consultation with Health Canada, would like to inform you of an important safety update to the Warnings & Precautions section of the Product Monograph for VOTRIENT®, regarding a change in frequency of serum liver test monitoring for hepatotoxicity. VOTRIENT® is a tyrosine kinase inhibitor indicated for the treatment of patients with metastatic renal cell (clear cell) carcinoma as first-line systemic therapy or as second line systemic therapy after treatment with cytokines for metastatic disease. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment